PL1819230T3 - Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia - Google Patents

Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia

Info

Publication number
PL1819230T3
PL1819230T3 PL05849361T PL05849361T PL1819230T3 PL 1819230 T3 PL1819230 T3 PL 1819230T3 PL 05849361 T PL05849361 T PL 05849361T PL 05849361 T PL05849361 T PL 05849361T PL 1819230 T3 PL1819230 T3 PL 1819230T3
Authority
PL
Poland
Prior art keywords
microparticles
derived
hemorrhage
treatment
control
Prior art date
Application number
PL05849361T
Other languages
English (en)
Inventor
Wenche Jy
Joaquin J Jimenez
Lawrence L Horstmann
Yeon S Ahn
Eugene Ahn
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of PL1819230T3 publication Critical patent/PL1819230T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05849361T 2004-12-07 2005-12-07 Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia PL1819230T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63341704P 2004-12-07 2004-12-07
EP05849361A EP1819230B1 (en) 2004-12-07 2005-12-07 Red cell-derived microparticles as hemostatic agents for the control of hemorrhage and for treatment of bleeding disorders
PCT/US2005/044064 WO2006062945A2 (en) 2004-12-07 2005-12-07 Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
PL1819230T3 true PL1819230T3 (pl) 2013-02-28

Family

ID=36578476

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05849361T PL1819230T3 (pl) 2004-12-07 2005-12-07 Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia

Country Status (9)

Country Link
US (1) US8105632B2 (pl)
EP (1) EP1819230B1 (pl)
JP (1) JP5204490B2 (pl)
AT (1) ATE555799T1 (pl)
DK (1) DK1819230T3 (pl)
ES (1) ES2390317T3 (pl)
PL (1) PL1819230T3 (pl)
PT (1) PT1819230E (pl)
WO (1) WO2006062945A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155764B1 (en) * 2004-12-07 2015-10-13 University Of Miami Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
DK2510946T3 (en) 2007-02-07 2015-11-02 Univ California Conjugates of synthetic fluorescent agonists and their applications
FR2917172B1 (fr) * 2007-06-07 2014-01-03 Inst Nat Sante Rech Med Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
US20090062233A1 (en) * 2007-08-09 2009-03-05 Xin Ji Modified starch material of biocompatible hemostasis
EP2449384B1 (en) * 2009-07-01 2016-04-20 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting cardiovascular mortality risk
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US20130316011A1 (en) * 2011-01-28 2013-11-28 University Of Miami Expanded Utility of Red Cell-Derived Microparticles (RMP) for Treatment of Bleeding
JP2012168012A (ja) * 2011-02-14 2012-09-06 Nippon Koden Corp 血管内皮障害を検査するための新規な検査方法および検査用キット
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US10004764B2 (en) * 2013-11-07 2018-06-26 University of Pittsburgh—of the Commonwealth System of Higher Education Red blood cell membrane-derived microparticles and their use for the treatment of lung disease
EP3068866B1 (en) 2013-11-16 2018-04-25 Terumo BCT, Inc. Expanding cells in a bioreactor
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
US10538738B2 (en) * 2014-05-19 2020-01-21 Eleftherios Papoutsakis Megakaryocytic particles and microparticles for cell therapy and fate modification of stem and progenitor cells
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
EP3265116B1 (en) * 2015-03-04 2021-06-02 University of Rochester Systemic and topical application of platelet microparticles to treat bleeding in trauma patients
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10543286B2 (en) 2015-10-07 2020-01-28 The Research Foundation For The State University Of New York Methods for increasing platelet count by inhibiting biliverdin IXβ reductase
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP6896516B2 (ja) * 2016-07-25 2021-06-30 シスメックス株式会社 血液分析装置および血液分析方法
WO2018102409A2 (en) 2016-11-30 2018-06-07 University Of Miami Rmp composition and methods of use
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
CN115768877A (zh) 2020-05-11 2023-03-07 斯特姆生物公司 与巨核细胞来源的细胞外囊泡相关的组合物和方法
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion
EP4329783A4 (en) 2021-04-26 2025-04-02 STRM.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
JP2025536478A (ja) * 2022-11-18 2025-11-06 ジョンシャン ユニバーシティ 体外血液凝固促進薬又は体外止血薬の調製における小胞の使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2227752C2 (ru) 1998-11-12 2004-04-27 Новолитикс Инк. Способы перекрытия кровотока и композиции для их реализации

Also Published As

Publication number Publication date
EP1819230A2 (en) 2007-08-22
EP1819230B1 (en) 2012-05-02
WO2006062945A3 (en) 2006-12-07
JP5204490B2 (ja) 2013-06-05
WO2006062945A2 (en) 2006-06-15
US8105632B2 (en) 2012-01-31
ES2390317T3 (es) 2012-11-08
DK1819230T3 (da) 2012-08-20
ATE555799T1 (de) 2012-05-15
EP1819230A4 (en) 2009-08-12
JP2008522974A (ja) 2008-07-03
PT1819230E (pt) 2012-08-07
US20080069807A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
PL1819230T3 (pl) Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MX2020012416A (es) Anticuerpos dirigidos contra il-33 y sus usos.
NZ701121A (en) Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
PH12015502388A1 (en) Compositions and methods for altering second messenger signaling
PH12020500343A1 (en) Pyruvate kinase activators for use in treating blood disorders
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
EP4442270A3 (en) Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
EA201691235A1 (ru) Модифицированные серпины для лечения нарушений свертываемости крови
EP4353311A3 (en) Shear-thinning compositions as an intravascular embolic agent
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
GEP201706741B (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
MX349265B (es) Composiciones antimicrobianas liquidas de baja formacion de espuma, modificadas reologicamente, y sus metodos de uso.
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
WO2017007886A3 (en) Compositions for inhibiting dux4 gene expression and uses thereof
TW200734306A (en) Novel compounds, their preparation and use
MX2019000456A (es) Inhibidores de calmodulin, inhibidores de chk2 e inhibidores de rsk para el tratamiento de trastornos ribosomales y ribosomatopias.
MX2020006533A (es) Inhibidores del receptor activado por proteasa-2.
EA032472B9 (ru) Композиция для укладки волос